Group items matching

in title, tags, annotations or url

The goal of this Funding Opportunity Announcement (FOA) is to continue to provide operations support for Biosafety Level 4 (BSL4) facilities to the National Biocontainment Laboratories at the University of Texas Medical Branch (UTMB) in Galveston, Texas and Boston University in Boston, Massachusetts. Operations support is provided in the following areas: facility maintenance and operations; biosecurity; environmental health and safety regulations and requirements; regulatory compliance; and specialized research support services. The NBLs will serve as a national resource for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs biodefense and emerging infectious diseases research efforts. Additionally, in times of a national biodefense or emerging infectious disease (EID) emergency, the NBLs may be expected to rapidly realign their activities to assist response efforts within the US under the direction of NIAID.

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

Access to quality assured diagnostics and laboratory services is critical to the effective diagnosis, treatment, and management of HIV and other HIV-related diseases, including TB. Achieving an AIDS-Free Generation and the UNAIDS 90-90-90 targets requires establishment and operationalization of laboratory and diagnostic networks, including strong and sustainable collaborations with partners.To date, PEPFAR-supported laboratory and integrated diagnostic network strengthening efforts have led to improved access to the quality diagnostic and patient monitoring services required to support the HIV clinical cascade. However, work remains to establish and maintain the partnerships and collaborations required to support these efforts. This NOFO will focus on building and strengthening sustainable networks and partnerships to support laboratory systems, policies, and data use in PEPFAR-supported countries; improving in-service laboratory safety and science competencies through quality training for laboratory professionals; collaborations across partner organizations, laboratory professionals, and clinicians; strengthened public health laboratory and diagnostic network capacity, quality, and functionality; and improved access to high quality and effective technical assistance (TA) resources.

The MBRP Clinical Trial Award mechanism is being offered for the first time in FY17.The objective of this Program Announcement is to explore innovative approaches to accelerate the translation of knowledge advances into new treatments for the Service members who sustain burn injuries. The results of the research funded through the FY17/18 MBRP Clinical Trial Award are expected to increase the body of knowledge and materiel products available to professionals and practitioners in health, medical science, and related fields. The research impact is expected to benefit both civilian and military communities.The FY17/18 MBRP Clinical Trial Award supports clinical research studies with the potential to have a major impact on the prevention, treatment, and mitigation of debilitating burn scars that are relevant to military personnel. The specific intent is to improve functional outcomes and/or assess clinical efficacy and safety of different treatment modalities (e.g., dressing topics, biologics, cell-based therapies, mechanical, photonics).

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention or treatment. For the purposes of this FOA, "intervention" is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that prevent acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected, or both.

The Ohio Affiliate of  Prevent Blindness is accepting applications for its 2018 Young Investigator Student Fellowship Awards for Female Scholars in Vision Research. The Fellowship Program is designed to provide support for outstanding female scientists committed to pursuing biomedical, behavioral or clinical research careers relevant to the mission of Prevent Blindness - to prevent blindness and preserve sight.  Grants will be awarded for the summer 2018 session.  Awards will range from $3000-$5000 depending upon the availability of funds. The deadline for receipt of applications is Feb. 15, 2018. Applicants must be post-baccalaureate students enrolled in a master's or doctorate program during the summer of 2018, female, citizens or permanent residents of the United States, and conducting their research with a recognized academic institution in the State of Ohio. Applications from diverse fields in the health sciences including, but not limited to ophthalmology, optometry, nursing, genetics, public health, nutrition, gerontology, and bioengineering, are appropriate to the goals of this fellowship award. The Ohio Affiliate of Prevent Blindness encourages fellowship applications which investigate public health issues related to the burden of eye-related health and safety topics.

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.

The MPS DC is expected to be the central clearinghouse for TC data management, and will incorporate novel approaches and technologies for data management, data mining and meta-analyses, and data sharing across many organs and tissues, diseases, data types, and TC platforms. The MPS Data center is expected to provide different levels of public and tiered access to TC information for basic and clinical researchers, academic and practicing physicians, the pharmaceutical industry, NIH, FDA and other government agencies, patients, and the lay public. The MPS Data Center will work with IQ Consortium members to develop and make available a secure, customizable coordinated data management system for collection, storage, and analyses of diverse data types from multiple TC platforms being developed and used for drug screening, safety and efficacy testing.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Immune Tolerance Network. The major goal of this Network is to develop tolerogenic approaches for the treatment and prevention of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated consequences of allotransplantation. The scope of research to be carried out includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approaches for the induction and maintenance of immune tolerance in humans; 2) the design and conduct of mechanistic studies and the development of tolerance assays as integral components of the clinical trials undertaken, including establishing and directing a consortium of laboratories; and one or more biospecimen repositories, and 3) the provision of bioinformatics, data collection, validation and analysis resources. In addition, on a limited basis, the Network may support focused product development and nonclinical studies (e.g., toxicology, pharmacology, pharmacokinetics, etc.) essential for the subsequent evaluation of promising tolerance induction approaches in humans.

The purpose of this FOA is to solicit applications for the Immune Tolerance Network. The major objective of the Network is to develop tolerogenic approaches for the treatment of disease in three clinical areas: asthma and allergic diseases; autoimmune diseases; and immune-mediated consequences of allotransplantation. The scope of research to be carried out by the Network includes: 1) the design and conduct of clinical trials at all phases to evaluate the safety and efficacy of investigational products and approaches for the induction and maintenance of immune tolerance in humans; 2) the design and conduct of mechanistic studies and the development of tolerance assays as integral components of the clinical trials undertaken; and establishment of biospecimen repositories 3) the provision of services on data management in collaboration with other resources provided by NIAID, bioinformatics analysis, and data sharing in a secure computing environment to support clinical trials and mechanistic studies. The Network may also support limited product development and nonclinical studies (e.g., toxicology, pharmacology, pharmacokinetics, etc.) essential for the subsequent evaluation of promising tolerance induction approaches in humans.

The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications proposing research that will promote the development and use of alternative test methods and strategies that address the "3Rs" of toxicity testing: 1) reduce, 2) refine, and/or 3) replace vertebrate animal testing. For the purposes of this RFA, alternative test methods refer to those that incorporate the "3Rs" principles. Pertinent research includes approaches such as analog/read-across techniques, mathematical models, and tiered testing approaches that integrate evidence from multiple sources to help accomplish these goals. In addition to the development of new alternative test methods and strategies, translational science approaches that use available data to develop and/or advance actionable approaches for risk assessment of chemicals are also critical. In this context, approaches that facilitate the use of existing animal data sources to reduce, refine, or replace the need for new vertebrate animal tests are as welcome as those that provide new data streams. The research activities to be funded under this announcement are intended to advance the science underpinning the use of non-vertebrate test methods, and to develop actionable alternative approaches to: 1) developmental toxicity tests in humans; 2) reproductive toxicity tests in humans; and/or 3) ecotoxicity tests.

The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area. Also listed under R03

The Prevent Blindness Ohio Young Investigator Student Fellowship Awards for Female Scholars in Vision Research provides training support for future generations of outstanding female scientists committed to pursuing biomedical, behavioral or clinical research careers relevant to the mission of Prevent Blindness Ohio - to prevent blindness and preserve sight.  The fellowship awards provide partial support to younger investigators, promoting the development of scientific skills that will lead to more substantial funding from other sources.